Temsirolimus with or without Megestrol Acetate and Tamoxifen for Endometrial Cancer: a Gynecologic Oncology Group Study

BACKGROUND: Preclinical evidence suggested that blockade of the PI3K/AKT/mTOR pathway might overcome resistance to hormonal therapy. METHODS: We performed a randomized phase II trial of intravenous temsirolimus 25 mg weekly versus the combination of weekly temsirolimus with a regimen of megestrol ac...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fleming, Gini F., Filiaci, Virginia L., Marzullo, Brandon, Zaino, Richard J., Davidson, Susan A., Pearl, Michael, Makker, Vicky, Burke, James J., Zweizig, Susan L., Van Le, Linda, Hanjani, Parviz, Downey, Gordon, Walker, Joan L., Reyes, Henry D., Leslie, Kimberly K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063288/
https://ncbi.nlm.nih.gov/pubmed/24456823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.01.015
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky